The global preclinical imaging market growth is driven by rising pharmaceutical and biotechnology research and development (R&D) spending. Pharmaceutical companies are increasingly investing in R&D to develop new drug candidates. Testing the efficacy and safety of these candidates at the preclinical stage requires advanced preclinical imaging techniques.
Request for a sample of this research report @ https://www.coherentmarketinsights.com/insight/request-sample/6634
Market Trends:
There has been a growing adoption of multimodal imaging systems that combine two or more imaging modalities such as PET/CT, PET/MRI, SPECT/CT, etc. in preclinical research
The ability to fuse functional and anatomical images provided by multimodal systems is driving their demand
Optical imaging techniques such as bioluminescence, fluorescence, and multispectral optoacoustic tomography (MSOT) are gaining increasing popularity in preclinical research
Applications such as detecting drug distribution in deep tissues, imaging tumor metastases, and assessing treatment response are favoring the adoption of optical imaging
Preclinical Imaging Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2023 |
$4.25 billion |
|
Estimated Value by 2031 |
$6.39 billion |
|
Growth Rate |
Poised to grow at a CAGR of 5.2% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Product, By Application, By End User |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Growing prevalence of chronic and infectious diseases • Technological advancements in preclinical imaging modalities • Increasing pharmaceutical and biotechnology R&D expenditure |
|
Restraints & Challenges |
• High cost of preclinical imaging modalities • Stringent regulations for product approval |
Market Opportunities:
Computed tomography (CT) imaging segment is estimated to account for over 30% of the total market share in 2024. CT imaging offers high-resolution anatomical images that help researchers better understand disease pathology and therapeutic response in small animal models. CT is widely used in oncology research for tumor detection, characterization, treatment monitoring, and response evaluation. The ability of CT to accurately quantify tumors and metabolic changes over time makes it an invaluable tool for preclinical cancer studies.
To Purchase a Comprehensive Report Analysis @ https://www.coherentmarketinsights.com/insight/buy-now/6634
Research and development segment accounted for approximately 40% of the total revenue in 2023. Preclinical imaging modalities such as CT, MRI, PET, and optical imaging play a crucial role in R&D by providing rapid, non-invasive techniques for disease modeling, drug discovery, treatment evaluation, and efficacy testing in small animals. They help accelerate the drug development process by reducing the time required for target identification, lead optimization, and candidate selection. The growing R&D investment by pharmaceutical and biotech companies is expected to drive the adoption of preclinical imaging solutions over the forecast period.
Key Market Takeaways:
The global preclinical imaging market is anticipated to witness a CAGR of 5.2% during the forecast period 2024-2031. This is owing to increasing investment in drug discovery and development by pharma companies and biotech startups.
By product, CT imaging segment is expected to hold a dominant position in 2024. This is owing to its high resolution imaging capabilities and widespread usage in oncology research.
By application, research & development segment is expected to hold a dominant position over the forecast period. This is due to the critical role of imaging in early stage drug development.
North America is expected to hold a dominant position over the forecast period, due to the presence of major market players and rising preclinical research expenditures in the region.
Key Players Insights
PerkinElmer
Bruker Corporation
Siemens AG
General Electric
TriFoil Imaging
MILabs BV
MR Solutions
Mediso Ltd
Agilent Technologies
VisualSonics Inc.
Molecules.
Recent developments:
In September 2023, Revvity Inc. launched its new imaging portfolio that is designed to fuel innovation across various applications. It is used in preclinical research with the launch of three systems.
In May 2022, FUJIFILM VisualSonics Inc. announced the launch of Vevo F2 multi-modal, an innovative imaging system that is used in preclinical imaging.
Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/6634
About Us:
Coherent Market Insights leads into data and analytics, audience measurement,
consumer behaviors, and market trend analysis. From shorter dispatch to
in-depth insights, CMI has exceled in offering research, analytics, and
consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools
and custom-made research services, we empower businesses to move in the
direction of growth. We are multifunctional in our work scope and have 450+
seasoned consultants, analysts, and researchers across 26+ industries spread
out in 32+ countries.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
